Longevity science

Episodes

• Episode 1

  GLP-1s, Bryan Johnson's routine, and whether NAD is worth your money

  November 4, 2026

  Four longevity doctors on what they've seen in four years of prescribing GLP-1s, why influencer protocols don't translate to patients, and the case for and against NAD.

  Metabolic healthSupplementsLongevity scienceNutrition

Articles

• Article

  NAD+ precursors: blood levels rise, outcomes have not followed

  November 9, 2026

  What the NR and NMN trials measured, what changed, what didn't, and why there is no test for tissue NAD+.

  SupplementsLongevity science

• Article

  Prioritizing health interventions: what an N of 1 cannot tell you

  November 7, 2026

  Bryan Johnson tests dozens of things on himself at once. Why that design can't assign credit, and what the population data say to fix first.

  Longevity scienceStrength and exercise

• Article

  Gray-market peptides, retatrutide, and the difference between a drug and a vial

  November 6, 2026

  Retatrutide is unapproved, so every vial sold under that name is unregulated. What the testing shows, and what the evidence for most peptides looks like.

  SupplementsMetabolic healthLongevity science

• Article

  GLP-1 medications beyond weight loss: how far do the benefits extend?

  November 4, 2026

  Heart, kidney, liver, sleep apnea, and two stranger findings. Which GLP-1 benefits are explained by weight loss, and which are not.

  Metabolic healthLongevity science

All topics